公开(公告)号：CA2756053A1

公开(公告)日：2010-01-14

申请号：CA2756053

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

IPC: A61K39/39 ,  A61K31/70 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (.alpha.- GalCer) analogs, and their use as immunotherapies, adju-vants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cy-tokine response in a subject includes administer-ing an effective amount of a compound to a sub-ject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1 :; or a pharmaceutically acceptable salt thereof; forming a complex between the com-pound and the antigen-presenting cell, wherein the formation of the complex results in the activa-tion of a receptor on the lymphocyte; and activat-ing the lymphocyte to produce the cytokine re-sponse.

公开(公告)号：GB2461656B

公开(公告)日：2012-11-21

申请号：GB0917142

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

IPC: C07H15/18 ,  A61K31/7034 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P43/00

公开(公告)号：WO2010006315A3

公开(公告)日：2010-03-25

申请号：PCT/US2009050328

申请日：2009-07-10

Applicant: ACADEMIA SINICA ,  WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

IPC: A61K39/39 ,  A61K31/70 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

CPC classification number: C07H15/18 ,  A61K31/7034 ,  A61K39/0011 ,  A61K2039/57

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (a- GalCer) analogs, and their use as immunotherapies, adjuvants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1 :; or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.

Abstract translation: 本公开内容涉及合成的α-半乳糖神经酰胺（a-GalCer）类似物，以及它们作为免疫疗法，佐剂和抗病毒，抗菌和抗癌剂的用途。 一方面，在受试者中激活细胞因子应答的方法包括向受试者施用有效量的化合物，其中所述受试者具有包括细胞群的适应性免疫系统，所述群体包括至少一种淋巴细胞和 至少一种抗原呈递细胞，并且其中所述化合物由式1的结构表示： 或其药学上可接受的盐; 在化合物和抗原呈递细胞之间形成复合物，其中复合物的形成导致淋巴细胞上受体的活化; 并激活淋巴细胞以产生细胞因子反应。

公开(公告)号：AU2009268381B2

公开(公告)日：2016-04-21

申请号：AU2009268381

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： HUNG JUNG-TUNG ,  LIN KUN-HSIEN ,  YU ALICE ,  JAN JIA-TSRONG ,  CHANG YA-JEN ,  LIN YI-LING ,  WONG CHI-HUEY ,  CHENG Y S EDMOND

IPC: A61K31/70 ,  A61K39/39 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (α- GalCer) analogs, and their use as immunotherapies, adjuvants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1 :; or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.

公开(公告)号：AU2009268381A1

公开(公告)日：2010-01-14

申请号：AU2009268381

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： HUNG JUNG-TUNG ,  LIN YI-LING ,  JAN JIA-TSRONG ,  WONG CHI-HUEY ,  CHENG Y S EDMOND ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN

IPC: A61K31/70 ,  A61K39/39 ,  A61P31/04 ,  A61P31/16 ,  A61P35/00

Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.

公开(公告)号：GB2461656A

公开(公告)日：2010-01-13

申请号：GB0917142

申请日：2009-07-10

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  CHENG Y S EDMOND ,  JAN JIA-TSRONG ,  LIN YI-LING ,  HUNG JUNG-TUNG

IPC: C07H15/18 ,  A61K31/7034 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P43/00

Abstract: The present disclosure relates to synthetic alpha-galaclosyl ceramide (alpha-GalCer) analogs, and their use as immunotherapies, adjuwants, and antiviral, antibacterial, and anticancer agents. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1:: or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.